Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555783 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
A Phase 2 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT06555783 is a Phase 2 study that has completed, run by Alkermes. The registered enrollment target is 93 participants.
The verdict
NCT06555783, a Phase 2 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Interventions
- DRUG Placebo
- DRUG ALKS 2680
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06555783
The ClinicalTrials.gov registry entry for NCT06555783 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06555783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06555783 about?
NCT06555783 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2". The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
What is the current status of trial NCT06555783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2024-07-26. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT06555783?
The interventions under investigation include: Placebo (DRUG), ALKS 2680 (DRUG).
Who is sponsoring clinical trial NCT06555783?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.